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AbsTrACT
Introduction Peripheral nerve stimulation (PNS) 
has historically been used to treat chronic pain, but 
generally requires implantation of a permanent system 
for sustained relief. A recent study found that a 60- day 
PNS treatment decreases post- amputation pain, and the 
current work investigates longer- term outcomes out to 
12 months in the same cohort.
Methods As previously reported, 28 traumatic lower 
extremity amputees with residual and/or phantom 
limb pain were randomized to receive 8 weeks of PNS 
(group 1) or 4 weeks of placebo followed by a crossover 
4 weeks of PNS (group 2). Percutaneous leads were 
implanted under ultrasound guidance targeting the 
femoral and sciatic nerves. During follow- up, changes in 
average pain and pain interference were assessed using 
the Brief Pain Inventory–Short Form and comparing with 
baseline.
results Significantly more participants in group 1 
reported ≥50% reductions in average weekly pain 
at 12 months (67%, 6/9) compared with group 2 at 
the end of the placebo period (0%, 0/14, p=0.001). 
Similarly, 56% (5/9) of participants in group 1 reported 
≥50% reductions in pain interference at 12 months, 
compared with 2/13 (15%, p=0.074) in group 2 at 
crossover. Reductions in depression were also statistically 
significantly greater at 12 months in group 1 compared 
with group 2 at crossover.
Conclusions This work suggests that percutaneous 
PNS delivered over a 60- day period may provide 
significant carry- over effects including pain relief, 
potentially avoiding the need for a permanently 
implanted system while enabling improved function in 
patients with chronic pain.
Trial registration number NCT01996254.
InTrOduCTIOn
Chronic pain is a prevalent and costly condition 
estimated to occur in over 30% of the popula-
tion.1 Chronic pain frequently causes disability and 
depression, and has a strong negative correlation 
with qualify of life.2 Peripheral nerve stimulation 
(PNS) has been successful in treating many chronic 
pain conditions,3 including nerve injury, complex 
regional pain syndrome, occipital neuralgia, 
and post- surgical pain, but conventional PNS 
has historically been limited by invasiveness and 
complications.4
Conventional neurostimulation systems, 
including PNS and spinal cord stimulation (SCS), 
have been found to produce sustained pain relief 
when implanted and used long term. However, 
opportunities have been rare to study the sustained 
effects of limited durations of stimulation on 
chronic, intractable pain. Patients with favorable 
responses during short- term stimulation trials 
typically progress to system implantation, and 
patients who have implanted systems deactivated or 
explanted often do so because of loss of therapeutic 
effect or complications like hardware failures.4 In 
studies evaluating the carry- over effects of PNS 
or SCS, only short stimulation periods (minutes 
to hours) were tested, and Wolter et al noted that 
there are no data on the duration of post‐SCS pain 
relief in humans.5 6
A novel PNS system that is now Food and Drug 
Administration (FDA)- cleared delivers stimula-
tion percutaneously for up to 60 days before the 
removal of the stimulating leads.7 8 The system was 
designed to overcome many of the limitations of 
conventional PNS systems, aiming to reduce inva-
siveness by placing leads percutaneously (typically 
with ultrasound guidance) and reduce infection 
rates and the loss of therapeutic effect due to lead 
migration by employing a flexible, open- coil lead 
placed remote from the target nerve.7–10 The devel-
opment of such a system has enabled the evaluation 
of long- term relief of pain following a PNS treat-
ment that significantly exceeds the average length 
of a percutaneous stimulation trial (4–7 days).
A multicenter, randomized, double- blind, 
placebo- controlled trial was conducted to evaluate 
changes in chronic pain and functional outcomes 
following amputation up to 12 months after a 
60- day PNS treatment. Post- amputation pain, 
including residual limb pain (RLP) and phantom 
limb pain (PLP), is commonly neuropathic in 
origin, though RLP may also have non- neuropathic 
etiologies.11 The primary endpoint of the study was 
previously reported to be positive, finding that a 
greater proportion of participants receiving 4 weeks 
of PNS reported substantial (≥50%) reductions in 
pain compared with those receiving 4 weeks of 
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placebo to a statistically significant degree.12 The current work 
presents the long- term follow- up of the study cohort through 12 
months, prospectively evaluating secondary outcomes including 
sustained reductions in pain, pain interference, and depression, 
and patient- reported global improvement, and exploring the 
unique mechanisms that may underlie the maintenance of pain 
relief following the 60- day treatment.
MATerIAls And MeThOds
study design and population
This multicenter, randomized, double- blind, placebo- controlled, 
partial- crossover study was designed to collect data regarding 
the safety and effectiveness of percutaneous PNS for chronic 
pain in amputees. The study was approved by the FDA under an 
Investigational Device Exemption, and the PNS system is now 
FDA- cleared.
Prospective participants at six enrolling centers in the USA 
provided written consent and were assessed for eligibility. Partic-
ipants were traumatic lower extremity amputees ≥18 years of 
age with moderate- to- severe (≥4 on a 0–10 pain rating scale13) 
RLP and/or PLP. Other than requiring a healed residual limb 
without comorbidities, there were no constraints on time since 
amputation. Key exclusion criteria included changes in pain 
medications in the previous 4 weeks, Beck Depression Inven-
tory II (BDI- II) score >20, compromised immune system (eg, 
HIV, chemotherapy, immunosuppressive medications), diabetes 
mellitus type I or II, implanted electrical stimulation devices, 
anticoagulation therapy (aside from aspirin or warfarin with 
an international normalized ratio (INR) ≤1.5), history of a 
bleeding disorder, history of valvular heart disease, pregnancy, 
confounding central nervous system (CNS) disorders, allergy to 
local anesthetic agents or skin- contact materials, history of recur-
rent skin infection, botulinum toxin injection in the previous 3 
months in the affected limb, and steroid injection in the previous 
6 weeks in the affected limb. Continued use of all baseline pain 
medications was permitted at or below the documented baseline 
dosages.
A 7- day baseline pain diary was completed to determine 
average daily RLP and PLP scores and document baseline dosage 
of pain medications. Qualifying participants were randomized 
1:1 in blocks of two to one of two groups, stratified by enrolling 
institution, using a masked allocation sequence generated by the 
study’s data capture system. Treating physicians were unmasked, 
while participants and outcomes assessors were masked to group 
assignment. Group 1 (PNS) received active stimulation for 4 
weeks, while group 2 (placebo) received sham stimulation. After 
the first 4 weeks, group 1 received four additional weeks of stim-
ulation (up to 60 days total) and group 2 crossed over to receive 
active stimulation for 4 weeks. After the 8- week treatment 
period, all leads were removed and both groups were followed 
monthly for up to 12 months from the initial implantation.
Interventions
Percutaneous PNS leads were implanted under ultrasound guid-
ance targeting the femoral and sciatic nerves.10 Each introducer 
entry site was prepped using aseptic technique, and cutaneous 
local anesthesia was administered, taking care to not deliver 
anesthetic to the deeper target nerve where it may affect the 
stimulation response. The femoral nerve was targeted with 
the participant supine using a lateral approach approximately 
1–2 cm distal to the inguinal crease. The lead was implanted 
remote (0.5–3 cm) from the nerve to enable selective activa-
tion of large- diameter sensory fibers.7 8 10 The sciatic nerve was 
targeted with the participant prone or in the lateral decubitus 
position. Ultrasonic landmarks included the greater trochanter, 
ischial tuberosity, femur, and/or popliteal artery to guide loca-
tion of the lead remote from the nerve proximal to the level 
of amputation. Modifications to these approaches were made 
at the discretion of the investigator based on patient- specific 
anatomy.
In the PNS group, a monopolar needle electrode was typi-
cally inserted to within 0.5–3 cm of the targeted nerve. Test 
stimulation (asymmetric charge- balanced biphasic pulse train, 
100 Hz, 1–30 mA, 10–200 µs) was delivered to confirm that 
comfortable stimulation- evoked sensations could be induced in 
the regions of RLP and/or PLP. The test needle was redirected 
in small increments to optimize the coverage of comfortable 
sensations and minimize or avoid undesired sensations (eg, local 
or distal motor activation, local or distal discomfort). Once the 
location was optimized, the needle electrode was removed and a 
fine wire coiled lead (MicroLead; SPR Therapeutics, Cleveland, 
Ohio, USA) preloaded in a 20G introducer needle was directed 
to the same location. Correct lead location was confirmed by 
again testing stimulation through the lead to evoke comfortable 
sensations in the regions of RLP and/or PLP, and the introducer 
needle was withdrawn to implant the lead. The lead was coiled 
outside the skin, trimmed, and the exit site was covered with an 
occlusive bandage (Tegaderm; 3M, St. Paul, Minnesota, USA). 
Leads were connected to external, wearable pulse generators 
(SPRINT PNS System; SPR Therapeutics) mounted on the body 
using an adhesive hydrogel pad that also served as the return 
electrode. Group 1 received stimulation that was programmed 
to evoke comfortable sensations in the regions of RLP and PLP 
using the same waveform and parameter range as the test stim-
ulation, and participants were permitted to adjust stimulation 
intensity during the 60- day treatment within a range set for them 
by the study staff.
In group 2, test needles and percutaneous leads were implanted 
under ultrasound guidance to a location a similar distance from 
the targeted nerve, but no stimulation was delivered during the 
procedure or at any time during the first 4 weeks of the treat-
ment period. The PNS system was equipped with a sham mode 
in which the stimulator appeared to operate normally (eg, the 
screen indicated that stimulation was on, intensity values on 
the screen could be increased or decreased, and the battery life 
indicator decreased at a predetermined rate requiring regular 
battery changes consistent with actual use and battery life in the 
PNS group), but the pulse generator did not deliver any stim-
ulation. Mock stimulation testing during the procedure could 
therefore be applied by turning on the stimulator, increasing the 
intensity value shown, and soliciting feedback from the patient 
to simulate the procedural experience of participants in group 
1.
All participants were instructed to use the stimulation contin-
uously and were assessed weekly during the 8- week treatment 
period. After 4 weeks, group 2 crossed over and began receiving 
active stimulation for the remaining 4 weeks of the treatment 
period. Leads were electively replaced at the time of crossover 
if it was determined one or more of the original leads implanted 
without active stimulation testing did not produce comfortable 
sensations in the regions of pain or clinically significant pain 
relief when stimulation was turned on. In addition, in both 
groups, leads were replaced if grossly dislodged. At the end 
of the 8- week treatment period (up to 60 days total), investi-
gators removed all leads. Participants were followed monthly 
for 10 additional months (12 months from the time of lead 
implantation).
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Figure 1 Flowchart showing the progression of participants in the Full Analysis Set. PNS, peripheral nerve stimulation.
Outcomes assessments
The primary outcome—reported previously12—was the 
proportion of participants in each group who were treatment 
responders, which was defined as a ≥50% reduction in average 
daily pain score during weeks 1–4 of the treatment period in all 
areas of postamputation pain (RLP and/or PLP) that had base-
line average pain scores ≥4. The primary safety outcome was 
the occurrence of device- related and procedure- related adverse 
events assessed at all visits.
The present report focuses on several key predefined secondary 
outcomes through the 12- month follow- up period. RLP, PLP, and 
pain interference during follow- up were assessed for the 1 week 
prior to each time point using questions 5 and 9 of the Brief Pain 
Inventory–Short Form and compared with baseline. The propor-
tion of subjects in group 1 with sustained reductions ≥50% at 
months 3–12 was compared with the proportion of subjects in 
group 2 with reductions ≥50% at the end of the placebo period. 
Patient Global Impression of Change (PGIC) and BDI- II scores 
were also assessed throughout the study follow- up period. Data 
on primary and secondary efficacy outcomes were collected by a 
disinterested assessor blinded to treatment allocation.
statistical analyses
All participants meeting eligibility criteria at the time of lead 
placement were included in a Full Analysis Set evaluating primary 
and secondary efficacy endpoints. Responder rates for reductions 
in pain and pain interference in the follow- up period were eval-
uated in a Long- Term Analysis population in which participants 
were considered treatment failures if they terminated early due 
to a return of pain. Missing data were handled by multiple impu-
tation using a regression model in PROC MI (SAS, Cary, North 
Carolina, USA) that included age, gender, ethnicity, race, time 
since amputation, level of amputation (above or below knee), 
and baseline average residual and phantom pain intensities as 
covariates. Primary safety endpoint analysis was performed on a 
population consisting of all participants who underwent a study 
procedure.
The study was funded with a grant from the United States 
Department of Defense, and enrollment was completed with 28 
subjects at the close of the grant funding period. Proportional 
and categorical data were compared between groups using a 
two- sided Fisher’s exact test with α=0.05. Continuous data 
were compared between groups using a two- sample Wilcoxon 
test with α=0.05. Proportional and continuous data were 
compared within group 2 (post- crossover vs placebo) using an 
exact McNemar’s test and a Wilcoxon signed- rank test, respec-
tively. Secondary outcomes were not adjusted for multiple 
comparisons. Summary statistics are presented as average (SD). 
Predefined statistical analyses were performed by an indepen-
dent biostatistician. Adverse events were adjudicated by an inde-
pendent medical monitor.
resulTs
study population
Enrollment occurred from March 2015 to March 2018, with 
47 consenting participants assessed for eligibility. Of these, 
28 participants were randomized to group 1 (n=14) or group 
2 (n=14) (figure 1). Two participants, both in group 1, were 
excluded from efficacy analyses due to changes in eligibility 
prior to implantation. The Full Analysis Set therefore included 
26 participants (group 1, n=12; group 2, n=14). Nine partic-
ipants in group 1 and six in group 2 completed the 12- month 
follow- up period (figure 1), and demographics and baseline 
 o
n
 N
ovem
ber 20, 2019 by guest. Protected by copyright.
http://rapm
.bmj.com/
R
eg Anesth Pain M
ed: first published as 10.1136/rapm
-2019-100937 on 17 Novem
ber 2019. Downloaded from
 
4 Gilmore CA, et al. Reg Anesth Pain Med 2019;0:1–8. doi:10.1136/rapm-2019-100937
Original article
Table 1 Demographics and baseline characteristics in the Full 
Analysis Set
Overall
(n=26)
Group 1
(n=12)
Group 2
(n=14) P value
Age, mean (SD), years 46.5 (12.7) 48.3 (12.3) 45.0 (13.2) 0.571
Female, % 23 17 29 0.652
Time since amputation, mean (SD), 
years
7.0 (6.6) 6.4 (4.6) 7.5 (8.1) 0.877
Time since onset of RLP, mean (SD), 
years
7.1 (6.9) 5.9 (4.4) 8.2 (8.6) 0.735
Time since onset of PLP, mean (SD), 
years
7.0 (6.8) 6.3 (4.9) 7.5 (8.1) 0.978
Level of amputation 0.021
  Above knee, n (%) 15 (58) 10 (83) 5 (36)
  Below knee, n (%) 11 (42) 2 (17) 9 (64)
Treatment history (% currently in use, % 
previously in use)
  
  Opioid medication 42, 50 42, 50 43, 50 >0.999
  Non- opioid medications 65, 27 67, 25 64, 29 >0.999
  Surface stimulation 0, 31 0, 33 0, 29 >0.999
  Spinal cord stimulation 0, 0 0, 0 0, 0 –
  Physical therapy 4, 81 0, 83 7, 79 >0.999
  Acupuncture 0, 8 0, 8 0, 7 >0.999
  Steroid injection 0, 15 0, 8 0, 21 0.598
  Botulinum toxin injection 0, 0 0, 0 0, 0 –
  Nerve block 0, 19 0, 17 0, 21 >0.999
  Other 4, 8 0, 17 7, 0 0.337
PLP, phantom limb pain; RLP, residual limb pain.
Figure 2 (A) Proportion of participants at each month in group 1 
reporting ≥50% reductions in all qualifying regions of residual limb pain 
(RLP) and phantom limb pain (PLP). *P<0.05 compared with proportion 
in group 2 at the end of the placebo period (EOP). (B) Average RLP and 
PLP scores in group 1 responders with ≥50% reductions in RLP or PLP 
at each month.
Table 2 Average residual limb pain
Group 1 Group 2*
Average rlP
(sd, n)
Average 
reduction from 
bl (sd)
Average rlP
(sd, n)
Average 
reduction from 
bl (sd)
Baseline 6.4 (1.0, 7) n/a 6.4 (1.3, 11) n/a
Week 4 4.2 (2.6, 7) 2.1 (2.6) 4.8 (1.7, 11) 1.7 (1.6)
Week 8 (EOT) 3.9 (1.7,7) 2.5 (2.2) 4.8 (2.2, 11) 1.7 (1.8)
Month 3 2.4 (1.5, 5) 4.0 (1.2)† 4.8 (3.4, 8) 1.0 (2.9)
Month 12 2.3 (1.2, 3) 4.3 (1.5)† 3.2 (2.5, 4) 1.0 (2.0)
*Group 2 crossed over at week 4 to receive 4 weeks of active stimulation.
†P<0.05 compared with group 2 at the end of the placebo period.
BL, baseline; EOT, end of treatment; n/a, not applicable; RLP, residual limb pain.
characteristics for this subset are included in online supplemen-
tary table 1.
Participants were lower extremity amputees due to trauma (eg, 
motor vehicle accident, gunshot, fall injury) with an average of 
7.0 (SD 6.6) years since the time of amputation, and an average 
of 7.0 and 7.1 years since onset of RLP and PLP (table 1). The 
distribution of participants with amputations above the knee 
versus below the knee was significantly different between groups 
(table 1). Two participants were bilateral amputees, but each 
qualified for lead implantation (ie, had baseline RLP and/or PLP 
≥4 at baseline) on only one side. The average baseline RLP score 
among qualifying participants was 6.4 (SD 1.0) in group 1 (n=7) 
and 6.4 (SD 1.3) in group 2 (n=11). The average baseline PLP 
score among qualifying participants was 6.9 (SD 1.7) in group 1 
(n=11) and 6.8 (SD 1.7) in group 2 (n=13). Participants previ-
ously used or were currently using a wide range of opioid, non- 
opioid, and other therapies for their post- amputation pain, most 
notably opioid oral medications (92%), non- opioid oral medica-
tions (92%), and physical therapy (85%).
Average residual and phantom pain
The proportion of participants in group 1 reporting ≥50% pain 
relief was significantly greater at each of months 3–12 compared 
with the proportion in group 2 at the end of the placebo period 
(figure 2). In particular, at 12 months, 67% (6/9, p=0.001) of 
participants in group 1 had sustained reductions of ≥50% in 
average pain in all qualifying regions of RLP and PLP over the 
week prior to the 12- month visit. No participants in group 2 
(0%, 0/14) reported ≥50% reductions in average weekly pain at 
the end of the placebo period.
The primary endpoint evaluated pain in all areas (RLP and/
or PLP) that qualified with pain ≥4 at baseline. Some patients 
qualified to be evaluated for RLP, PLP, or both. The reductions 
among those that qualified for RLP (table 2) or PLP (table 3) 
were significantly greater in group 1 during follow- up compared 
with group 2 during the placebo period. The average reduc-
tion in RLP at 12 months was 64% among group 1 responders 
(100%, 3/3), and the average reduction in PLP at 12 months 
was 77% among group 1 responders (56%, 5/9) (figure 2). All 
participants in group 1 had moderate- to- severe pain at baseline 
(RLP and/or PLP ≥4).13 Eight of 10 (80%) participants who 
completed the 8- week treatment had their pain reduced to mild 
or no pain (BPI-5 <4),13 and those categorical reductions were 
sustained in 67% (6/9) of subjects at 12 months (figure 3).
Out of a total of 260 possible visits (26 subjects in the Full 
Analysis Set with 10 monthly follow- up visits per subject), a total 
of 10 visits were missed for which pain and pain interference 
responder status was imputed. At month 12, only one visit was 
missed and required imputation. The missed visit at month 12 
occurred in a group 1 subject who reported 100% PLP and RLP 
relief at months 3–5 and months 7–11 and was imputed as a 
responder (≥50% relief) at months 6 and 12.
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Table 4 Beck Depression Inventory II scores
Group 1 Group 2*
Average bdI- II
(sd, n)
Average 
reduction from 
bl (sd)
Average bdI- II
(sd, n)
Average 
reduction from 
bl (sd)
Baseline 7.6 (6.0, 12) n/a 12.6 (5.0, 14) n/a
Week 4 6.1 (5.0, 11) 1.8 (4.4)† 13.0 (8.2, 13) −0.2 (7.3)
Week 8 (EOT) 4.0 (4.3, 10) 4.2 (6.5)† 14.0 (12.6, 11) −1.7 (9.8)
Month 3 6.1 (8.7, 10) 1.3 (8.3)† 15.2 (11.6, 10) −2.4 (9.7)
Month 12 5.8 (6.0, 8) 2.5 (6.1)† 10.0 (16.2, 4) 2.2 (17.8)
*Group 2 crossed over at week 4 to receive 4 weeks of active stimulation.
†P<0.05 compared with group 2 at the end of the placebo period.
BDI- II, Beck Depression Inventory II; BL, baseline; EOT, end of treatment; n/a, not applicable.
Table 3 Average phantom limb pain
Group 1 Group 2*
Average PlP
(sd, n)
Average 
reduction from 
bl (sd)
Average PlP
(sd, n)
Average 
reduction from 
bl (sd)
Baseline 6.9 (1.7, 11) n/a 6.8 (1.7, 13) n/a
Week 4 3.6 (2.6, 11) 3.3 (1.9) 5.4 (2.3, 13) 1.5 (1.4)
Week 8 (EOT) 3.1 (2.8, 11) 3.8 (2.2)† 4.7 (2.4, 13) 2.2 (1.7)†
Month 3 2.9 (2.8, 10) 3.5 (2.3)† 5.3 (2.6, 10) 1.7 (2.4)
Month 12 3.8 (3.8, 8) 2.6 (3.7) 3.5 (2.6, 4) 2.0 (2.2)
*Group 2 crossed over at week 4 to receive 4 weeks of active stimulation.
†P<0.05 compared with group 2 at the end of the placebo period.
BL, baseline; EOT, end of treatment; n/a, not applicable; PLP, phantom limb pain.
Figure 3 Proportion of participants in group 1 who completed the 
8- week treatment, by severity of pain at baseline, end of treatment, and 
12 months. NRS, Numeric Rating Scale.
Figure 4 (A) Proportion of participants at each month in group 1 
reporting ≥50% reductions in pain interference in all qualifying regions 
of residual limb pain (RLP) and phantom limb pain (PLP). *P<0.05 
compared with proportion in group 2 at the end of the placebo 
period (EOP). (B) Average RLP and PLP interference scores in group 1 
responders with ≥50% reductions in RLP or PLP interference at each 
month.
Pain interference, PGIC, and depression
Fifty- six percent (5/9) of participants in group 1 reported ≥50% 
reductions in pain interference in all qualifying regions of RLP 
and PLP at the end of the 12- month follow- up, compared with 
18% (2/11, p=0.074) in group 2 at the end of the placebo 
period (figure 4). The average reductions in RLP and PLP inter-
ference in group 1 were clinically meaningful and sustained from 
the end of treatment through the 12- month follow- up (figure 4). 
Group 1 participants reported 39%–72% average reductions in 
the seven individual domains of pain interference at 12 months, 
including 55% reduction in the interference of pain with General 
Activity, 39% in Walking, 63% in Sleeping, and 65% in Enjoy-
ment of Life.
Participants in group 1 reported clinically and statistically 
significant reductions in average BDI- II score throughout the 
treatment period and the 12- month follow- up period compared 
with the average reduction in group 2 at the end of the placebo 
period (table 4). In group 1, the average BDI- II score was 55% 
lower than baseline at the end of 8 weeks of PNS and remained 
33% lower than baseline at 12 months (table 4). Similarly, the 
average global improvement reported by group 1 was largely 
sustained through the 12- month follow- up period (table 5).
Group 2 outcomes following crossover
The responder rate in group 2 through 12 months (17%, 1/6) 
did not significantly change compared with the placebo period. 
As previously reported, group 2 participants did report signifi-
cant improvement in average PLP (33% (SD 28) reduction from 
baseline, p=0.027 compared with weeks 1–4) and PGIC after 
crossing over to receive 4 weeks of active stimulation.12 No 
other significant improvements in pain or secondary outcomes 
were observed during follow- up after the completion of the 
4- week crossover treatment.
safety
There were no serious or unanticipated study- related adverse 
events (AEs). No new study- related AEs were reported in the 
follow- up period since the publication of the initial outcomes.12 
A total of 22 study- related events were reported in 46% (13/28) 
of participants who underwent lead implantation, including 21 
mild (96%), 1 moderate (4%), and no severe events (0%). The 
most common mild events were skin irritation or redness due 
to the adhesive bandages or pain due to implantation or stimu-
lation, and the one moderate event was pain due to stimulation 
that was resolved by reprogramming. Five leads were suspected 
to be fractured during removal. Lead remnants (100-µm- di-
ameter wire) are MR conditional and were monitored in situ, 
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Table 5 Patient Global Impression of Change
Group 1 Group 2*
Average PGIC
(sd, n)
Average PGIC
(sd, n)
Week 4* 1.4 (1.1, 11) 0.6 (1.3, 13)
Week 8 (EOT) 2.2 (0.9, 10)† 1.3 (1.0, 11)
Month 3 1.9 (0.9, 10)† 1.0 (0.8, 10)
Month 12 1.8 (1.3, 8) 1.2 (1.5, 4)
*Group 2 crossed over at week 4 to receive 4 weeks of active stimulation.
†P<0.05 compared with group 2 at the end of the placebo period.
EOT, end of treatment; PGIC, Patient Global Impression of Change.
similar to previous studies.8 12 14 15 No related sequelae or AEs 
were reported through 12 months.
dIsCussIOn
This report suggests that substantial (≥50%) relief of chronic 
pain, such as pain following amputation that may include neuro-
pathic and non- neuropathic components, and improvements in 
function and depression can be sustained through 12 months in 
a majority of participants who receive a 60- day PNS treatment. 
These results are particularly relevant given the refractory nature 
of chronic pain following amputation and the well- documented 
challenges in treating RLP and PLP effectively.16 17
The carry- over of pain relief in 67% of participants through 
12 months and significant reductions in pain interference and 
improvements in PGIC following up to 60 days of PNS are 
comparable with the pain relief and functional improvements 
reported using the same percutaneous PNS system in other 
chronic pain indications. Two randomized controlled trials 
demonstrated sustained pain- relieving effects of percutaneous 
PNS targeting the terminal branches of the axillary nerve for 
the treatment of chronic shoulder pain, including one study 
that followed participants for up to 12 months and found that 
78% of participants in the PNS treatment group maintained 
benefit.18 19 Sustained improvements in pain have also been 
noted in 67% (6/9) of participants with chronic axial low back 
pain following 60 days of percutaneous PNS remotely targeting 
the medial branches of the dorsal ramus, in addition to compa-
rable improvements in disability and pain interference.20 These 
similar findings across patient populations further support that 
sustained pain relief from 60 days of percutaneous PNS can be 
achieved across neuropathic and musculoskeletal pain etiologies.
One of the most notable findings of the present study was 
that 67% (6/9) of participants who received 8 weeks of PNS 
and completed follow- up reported ≥50% pain relief 12 months 
after the onset of PNS without a permanently implanted system 
(figure 2). Based on a recently proposed definition of remission of 
chronic pain (pain ≤3 for at least 6 months),21 55% (5/9) of partic-
ipants who received 8 weeks of PNS and completed follow- up 
reported remission of at least one qualifying region of RLP or PLP 
by 12 months. The long- term responder rate in the present work 
is similar to studies using conventional implanted PNS systems 
with average follow- up durations of 11.5–31 months, in which 
the proportions of participants reporting sustained pain relief 
≥50% were 39%–79% with a cumulative long- term responder 
rate of 60% (126 of 210 implanted).22–29 In those studies, a stim-
ulation trial over several days was often employed to identify and 
exclude non- responders, akin to an enriched enrollment design. It 
is important to recognize that the percutaneous PNS treatment in 
the present study did not require a trial phase or implantation of a 
permanent system, yet achieved similar long- term responder rates 
to conventional, permanently implanted stimulation systems. 
This 60- day percutaneous PNS treatment concept challenges the 
long- held notion in pain management that a permanent implant is 
required to produce outcomes that are sustained long term.
study limitations
Even though some outcomes showed improvement in group 2 
after crossover, the proportion of group 2 subjects reporting 
substantial pain relief did not increase after crossing over to 
receive active stimulation. Leads were originally implanted 
without stimulation feedback in placebo control subjects in 
order to maintain blinding during the placebo period, but lead 
replacement was optional and was not uniformly applied (only 
3/14 group 2 participants had both leads replaced at cross-
over).12 Therefore, it is probable that the subjects randomized 
to receive sham for the first 4 weeks (group 2) had leads with 
suboptimal insertion locations, resulting in suboptimal active 
stimulation during the crossover weeks 5–8. Use of stimulation 
feedback at the time of original lead placement in group 2 may 
have reduced the occurrence of suboptimal lead locations and 
improved outcomes after crossover, but the paresthesias expe-
rienced during testing may have compromised the blinding of 
group 2 subjects. Alternately, consistent replacement of leads at 
the time of crossover in future studies would ensure accurate 
lead placement for active stimulation and optimal coverage of 
regions of pain with stimulation- evoked sensations.
Although the pain relief and pain interference outcomes were 
clinically meaningful and statistically significant, the sample sizes 
made some outcomes difficult to interpret, such as the trend in 
both group 1 and group 2 towards greater pain relief during 
follow- up compared with the end of treatment, especially at 
month 12 (tables 2 and 3). It is possible that the loss of some 
participants to follow- up influenced the average pain relief at 
later time points. Alternately, physical activity is commonly 
recognized as having an important role in pain relief,30 31 and 
participants reported substantial reductions in pain interference 
at the end of 8 weeks of PNS including 69% improvement in 
general activity, 81% improvement in walking ability, and 68% 
improvement in normal work. The further reductions in RLP 
and PLP during the follow- up period could be reflective of the 
maintenance of increased activity levels that may help sustain 
and improve on the initial reductions in residual and phantom 
limb pain.
Due to ethical considerations about unnecessary placebo 
administration, the treatment effects in group 1 during follow- up 
were compared with the placebo effect observed in group 2 
during the first 4 weeks of the treatment period (up to the time 
of crossover) and the comparisons between treatment effects 
during follow- up and placebo effects were therefore not time- 
matched. Since placebo effects tend to be maximal during the 
intervention period and diminish during follow- up,32 comparing 
the 12- month treatment effects to the control data at week 4 
may be a conservative statistical approach. Lastly, whereas the 
average differences in pain relief and pain interference responder 
rates were clinically and statistically significant, the small 
subgroups made some secondary analyses difficult to interpret. 
For example, not all subjects qualified for analysis of both RLP 
and PLP, and analyses fell shy of statistical significance at some 
time points despite substantial reductions in RLP, PLP, and pain 
interference. Analyses also did not specifically assess the neuro-
pathic components of pain, which could be used to determine 
treatment effects on neuropathic and non- neuropathic etiologies 
in conditions like RLP where both can occur.
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Proposed mechanisms for sustained pain relief
The sustained analgesic effects of the 60- day PNS treatment 
are believed to stem from spinal and supraspinal mechanisms 
engaged by the delivery of stimulation from the PNS system 
with leads placed remote (0.5–3 cm) from the targeted nerves. 
Conventional neurostimulation for analgesia is based on the 
theory that large- diameter myelinated afferent fibers are stimu-
lated in the periphery (for PNS) or the dorsal columns (for SCS) 
to activate a gating mechanism in the spinal dorsal horn that 
attenuates pain.33 However, the placement of conventional stim-
ulation leads in contact with or in close proximity to targeted 
neural structures limits the ability of stimulation to selectively 
activate large- diameter sensory fibers due to the neurophysiolog-
ical relationships between activation threshold, fiber diameter, 
and distance from the stimulation source.7 10 This limited acti-
vation has been particularly observed for SCS, where computa-
tional and experimental data support the notion that relatively 
few fibers in the dorsal column may be activated to create an 
analgesic effect before reaching discomfort thresholds, even 
though activation of larger numbers of targeted fibers may result 
in greater pain relief.34 35 It was theorized that a system designed 
specifically for use in the periphery with reversible implantation 
of leads remote from the target nerve (0.5–3 cm distant) may 
enable selective and comprehensive activation of a large propor-
tion of targeted fibers in peripheral nerves. Broader activation 
of large- diameter fibers by the PNS system in the present study 
may therefore confer an advantage in engaging spinal segmental 
mechanisms of pain relief (ie, more effectively closing the gate) 
compared with conventional stimulation therapies.
Neuropathic pain, and PLP in particular, has been suggested 
to involve maladaptive supraspinal structural and functional 
plasticity, including shifts in cortical sensory representations that 
correlate with the severity of pain.36 37 Selectively and preferen-
tially activating a significant number of large- diameter fibers in 
targeted peripheral nerves with a PNS system designed to deliver 
stimulation through remote lead placement may have two 
significant supraspinal effects that contribute to sustained pain 
relief. First, a review of recent results following nerve blocks 
to treat PLP suggests that aberrant plasticity can be transiently 
reversed by modulating painful signals from the periphery.38 A 
PNS system that stimulates through remotely placed leads may 
optimize that modulation, enabling more efficient reversal of 
aberrant plasticity by more comprehensively activating the spinal 
gating mechanism. Second, analysis of studies using cutaneous 
electromyography or sensorimotor training to provide sensory 
feedback to the CNS suggests that providing non- nociceptive 
input to the CNS can promote beneficial functional plasticity 
to correct imbalances in somatosensory processing and relieve 
chronic, centrally maintained pain.39 40 Whereas conventional 
neurostimulation systems induce afferent activation that is likely 
to be sparse and/or diffuse across multiple dermatomes,34 37 
sensory feedback mechanisms are most effective when afferent 
input is focal in the cortical area that represents the region of 
pain.37 40 41 By preferentially activating a significant number of 
large- diameter fibers that innervate the region of pain while 
avoiding activation of small- diameter fibers, stimulation with 
a PNS system whereby leads are placed remotely may provide 
non- nociceptive cortical input from the region of pain that is 
more robust and focal than conventional stimulation systems. 
Together, these supraspinal mechanisms are proposed to 
correct the imbalances in physiological input that initially lead 
to maladaptive cortical changes while also promoting bene-
ficial cortical plasticity to produce sustained pain relief and 
commensurate gains in quality of life and increases in activity 
that can have secondary pain- relieving benefits.
COnClusIOns
This multicenter, randomized, double- blinded, placebo- 
controlled, partial crossover study suggests that a 60- day percuta-
neous PNS treatment may provide sustained clinically significant 
relief of chronic pain following amputation and subsequent 
improvements in function and depression. The carry- over effects 
in pain and pain interference were achieved following short- 
term implantation of PNS leads that were removed after 60 days. 
Coupled with the strong safety profile both in this study and 
reported elsewhere,9 10 15 18 20 these results suggest that patients 
with pain, such as the neuropathic and non- neuropathic pain that 
commonly follow amputation, may receive significant benefit 
from this minimally invasive, reversible percutaneous PNS treat-
ment without the invasiveness and accompanying complications, 
costs, and risks of a permanently implanted system.
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